Working… Menu

Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02469090
Recruitment Status : Completed
First Posted : June 11, 2015
Last Update Posted : November 20, 2018
Information provided by (Responsible Party):

Brief Summary:
A 12-week, prospective, multi-center, randomized, double-blind, placebo controlled, Phase 3 study in L-Dopa responsive PD patients with motor fluctuations ("OFF" episodes), designed to determine the efficacy, safety and tolerability of APL-130277.

Condition or disease Intervention/treatment Phase
Parkinson Disease, Off Episodes Drug: APL-130277 Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 219 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
Actual Study Start Date : June 30, 2015
Actual Primary Completion Date : December 11, 2017
Actual Study Completion Date : December 11, 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: APL-130277
APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
Drug: APL-130277
Use to treat up to 5 "OFF" episodes per day
Other Name: Apomorphine Hydrochloride, Sublingual Thin Film

Placebo Comparator: Placebo
Matching placebo for APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
Drug: Placebo

Primary Outcome Measures :
  1. Mean change from pre-dose in MDS-UPDRS Part III Motor Examination (MDS-UPDRS MOTOR) at 30 minutes after dosing at the 12 week visit of the Maintenance Treatment Phase [ Time Frame: 30 minutes post-dose ]

Secondary Outcome Measures :
  1. Percentage of patients with a patient-rated full "ON" response within 30 minutes at the 12 week visit of the Maintenance Treatment Phase [ Time Frame: 30 minutes post-dose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female ≥ 18 years of age.
  • Clinical diagnosis of Idiopathic PD, consistent with UK Brain Bank Criteria.
  • Clinically meaningful response to L-Dopa with well-defined early morning "OFF" episodes, as determined by the Investigator.
  • Receiving stable doses of L-Dopa/carbidopa (immediate or CR) administered at least 4 times per day OR Rytary™ administered 3 times per day, for at least 4 weeks before the initial Screening Visit
  • No planned medication change(s) or surgical intervention anticipated during the course of study.
  • Patients must experience at least one well defined "OFF" episode per day with a total daily "OFF" time duration of ≥ 2 hours during the waking day, based on patient self-assessment.
  • Stage III or less on the modified Hoehn and Yahr scale in the "ON" state.
  • MMSE score > 25.

Exclusion Criteria:

A patient will not be eligible for study entry if any of the following exclusion criteria are met:

  • Atypical or secondary parkinsonism.
  • Previous treatment with any of the following: a neurosurgical procedure for PD; continuous s.c. apomorphine infusion; or Duodopa/Duopa.
  • Treatment with any form of s.c. apomorphine within 7 days prior to the initial Screening Visit (SV1). Patients that stopped s.c. apomorphine for any reason other than systemic safety concerns or lack of efficacy may be considered.
  • Contraindications to APOKYN®, or hypersensitivity to apomorphine hydrochloride or any of the ingredients of APOKYN® (notably sodium metabisulfite); Tigan® (trimethobenzamide hydrochloride; patients from US sites only); or domperidone (patients from non-US sites only).
  • Participation in a clinical trial within 30 days prior to the initial Screening Visit (SV1).
  • Currently taking selective 5HT3 antagonists (i.e., ondansetron, granisetron, dolasetron, palonosetron, alosetron), dopamine antagonists (excluding quetiapine or clozapine) or dopamine depleting agents.
  • Drug or alcohol dependency in the past 12 months.
  • History of malignant melanoma.
  • Clinically significant medical, surgical, or laboratory abnormality in the opinion of the Investigator.
  • Major psychiatric disorder including, but not limited to, dementia, bipolar disorder, psychosis, or any disorder that, in the opinion of the Investigator, requires ongoing treatment that would make study participation unsafe or make treatment compliance difficult.
  • History of clinically significant hallucinations during the past 6 months.
  • History of clinically significant impulse control disorder(s).
  • Dementia that precludes providing informed consent or would interfere with participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02469090

  Hide Study Locations
Layout table for location information
United States, Alabama
University of Alabama, Birmingham
Birmingham, Alabama, United States, 35233
United States, Arizona
Muhammed Ali Parkinson and Movement Disorder CenterBarrow Neurological
Phoenix, Arizona, United States
Movement Disorders Center of Arizona
Scottsdale, Arizona, United States, 85258
Mayo Clinic Arizona
Scottsdale, Arizona, United States, 85259
United States, California
The Parkinson's and Movement Disorder Institute
Fountain Valley, California, United States, 92708
UC Irvine Health Gottschalk Medical Plaza
Irvine, California, United States, 92697
Keck Medical Center at USC
Los Angeles, California, United States, 90033
The Research Center of Southern California
Oceanside, California, United States, 92056
United States, District of Columbia
MedStar Georgetown University Hospital
Washington, District of Columbia, United States, 20007
United States, Florida
Parkinsons Disease and Movement Disorders Center
Boca Raton, Florida, United States, 33486
University of Miami, Miller School of Medicine
Miami, Florida, United States, 33136
Parkinson's Disease Treatment Center of Southwest Florida
Port Charlotte, Florida, United States, 33980
USF Parkinson's Disease and Movement Disorder Center
Tampa, Florida, United States, 33613
United States, Georgia
Emory University Department of Neurology
Atlanta, Georgia, United States, 30329
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
Rush University Medical Center
Chicago, Illinois, United States, 60612
Central DuPage Hospital - Neurodegenerative Clinic - Movement Disorders Center
Winfield, Illinois, United States, 60190
United States, Kansas
Kansas University Medical Center - Department of Neurology
Kansas City, Kansas, United States, 66160
United States, Kentucky
University of Kentucky
Lexington, Kentucky, United States, 40536
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21287
United States, Michigan
QUEST Research Institute
Farmington Hills, Michigan, United States, 48334
Northern Michigan Neurology
Traverse City, Michigan, United States, 49684
Henry Ford Hospital
West Bloomfield, Michigan, United States, 48322
United States, New York
Columbia University Medical Center - Neurological Institute, Movement Disorders
New York, New York, United States, 10032
United States, North Carolina
Raleigh Neurology Associates, P.A.
Raleigh, North Carolina, United States, 27607
Wake Forest Baptist Health
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45219
Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Oklahoma
The Movement Disorder Clinic of Oklahoma
Tulsa, Oklahoma, United States, 74136
United States, Pennsylvania
Jefferson University Hospital Philadelphia
Philadelphia, Pennsylvania, United States, 19107
United States, Virginia
University of Virginia, Adult Neurology
Charlottesville, Virginia, United States, 22903
United States, Washington
Evergreen Health
Kirkland, Washington, United States, 98034
Canada, Ontario
UHN Toronto Western Hospital
Toronto, Ontario, Canada, M5T 2S8
Sponsors and Collaborators
Layout table for investigator information
Study Director: CNS Medical Director Sunovion

Layout table for additonal information
Responsible Party: Sunovion Identifier: NCT02469090     History of Changes
Other Study ID Numbers: CTH-300
First Posted: June 11, 2015    Key Record Dates
Last Update Posted: November 20, 2018
Last Verified: November 2018
Keywords provided by Sunovion:
Parkinson Disease, off episodes
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action